^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Magicell-NK

    Associations

    News

    Trials
    Company:
    Medigen Biotech
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/refractory gastrointestinal cancer. (ASCO 2023)
    Ex vivo expanded human peripheral blood NK (Magicell-NK, Medigen, Taiwan) cells were used in this study. Our findings suggest that a non-viral based CDH17 CAR-NK cell therapy could be a potential allogeneic, off-the-shelf CAR-NK therapy candidate in GI cancer and support the rationale of further investigating it in vivo and clinical trials.
    IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1) • CDH17 (Cadherin 17)
    |
    CDH17 CAR-NK cell therapy • CHM 2301 • Magicell-NK
    almost2years
    A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study (clinicaltrials.gov)
    P1, N=18, Recruiting, Medigen Biotechnology Corporation
    New P1 trial • Preclinical • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CA 19-9 (Cancer antigen 19-9)
    |
    Magicell-NK